Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 8,813,021
  • Shares Outstanding, K 153,190
  • Annual Sales, $ 745,690 K
  • Annual Income, $ -208,440 K
  • 36-Month Beta 2.23
  • Price/Sales 11.84
  • Price/Cash Flow 0.00
  • Price/Book 7.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.34 +2.47%
on 06/30/17
61.31 -5.84%
on 07/05/17
+0.07 (+0.12%)
since 06/21/17
3-Month
53.64 +7.62%
on 04/27/17
63.40 -8.94%
on 06/09/17
+1.16 (+2.05%)
since 04/21/17
52-Week
41.93 +37.68%
on 10/17/16
63.40 -8.94%
on 06/09/17
+8.76 (+17.89%)
since 07/21/16

Most Recent Stories

More News
Shares of ALKS Up 57.7% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Alkermes Plc (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 16 months, Alkermes Plc has returned 57.66% as of today's recent price of $58.84.

ALKS : 57.73 (+0.35%)
Technical Reports on Drug Delivery Equities -- PetMed Express, Adamis Pharma, Delcath Systems, and Alkermes

If you want a Stock Review on PETS, ADMP, DCTH or ALKS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today's research on DailyStockTracker.com...

PETS : 40.54 (+3.98%)
ADMP : 4.80 (+3.23%)
DCTH : 0.14 (-6.67%)
ALKS : 57.73 (+0.35%)
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

CARA : 15.35 (-0.71%)
BMRN : 89.28 (+1.76%)
ACOR : 20.65 (-1.20%)
ALKS : 57.73 (+0.35%)
AMGN : 180.21 (+0.50%)
BIIB : 282.92 (+0.53%)
OPXA : 0.90 (-1.64%)
Alkermes Presents Phase III Data on Schizophrenia Candidate

Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

JNJ : 135.31 (-0.92%)
LLY : 84.66 (-0.11%)
AGN : 250.97 (+0.76%)
ALKS : 57.73 (+0.35%)
Alkermes Plc Up 55.4% Since SmarTrend Uptrend Call (ALKS)

SmarTrend identified an Uptrend for Alkermes Plc (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 15 months, Alkermes Plc has returned 55.41% as of today's recent price of $58.00.

ALKS : 57.73 (+0.35%)
Minerva On Track to Initiate Phase III Schizophrenia Study

Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.

AZN : 34.05 (+0.47%)
ACAD : 30.43 (+1.13%)
ALKS : 57.73 (+0.35%)
NERV : 7.85 (-4.27%)
Global Substance Abuse Treatment Market to Grow at a CAGR of 5.15% By 2021 - Key Vendors are Alkermes, Allergan, GSK & Pfizer

Research and Markets has announced the addition of the "Global Substance Abuse Treatment Market 2017-2021" report to their offering. The global substance abuse treatment market to grow at a CAGR of 5.15%...

AGN : 250.97 (+0.76%)
INSY : 11.98 (-2.68%)
AMPH : 18.45 (+2.96%)
ALKS : 57.73 (+0.35%)
Global Substance Abuse Treatment Market 2015-2017 & 2025 - Growth Trends, Key Players, Competitive Strategies and Forecasts

Research and Markets has announced the addition of the "Global Substance Abuse Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...

MYL : 39.17 (-0.81%)
RBGLY : 21.3500 (+3.34%)
AGN : 250.97 (+0.76%)
ALKS : 57.73 (+0.35%)
PFE : 33.48 (-0.18%)
Injectable Drug Delivery Market, 2024

Research and Markets has announced the addition of the "Global Injectable Drug Delivery Market - Trends and Forecast to 2024" report to their offering. Global Injectable Drug Delivery Market is Expected...

TRUMF : 38.1500 (-0.03%)
LLY : 84.66 (-0.11%)
BAX : 62.67 (-0.59%)
TEVA : 32.64 (+0.65%)
ALKS : 57.73 (+0.35%)
PFE : 33.48 (-0.18%)
Alkermes Has Returned 51.2% Since SmarTrend Recommendation (ALKS)

SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 15 months, Alkermes has returned 51.25% as of today's recent price of $56.45.

ALKS : 57.73 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Support & Resistance

2nd Resistance Point 58.54
1st Resistance Point 58.13
Last Price 57.73
1st Support Level 57.24
2nd Support Level 56.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.